Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ABBV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAbbVie raises FY2026 EPS guidance and dividend after Q3 revenue grows 10.3%
Filed October 30, 2026 · Period ending October 30, 2026 · ~1 min read
Key Changes
-
high
Q3 2026 worldwide net revenues rose 10.3% to $17.404 billion, with adjusted diluted EPS of $3.82, more than double the prior-year quarter.
Exhibit 99.1 view on EDGAR → -
high
Full-year 2026 adjusted diluted EPS guidance raised to $13.95–$13.99 from $13.76–$13.96, including a $0.69 per share IPR&D and milestones headwind.
Exhibit 99.1 view on EDGAR → -
medium
Quarterly dividend increased 5.2% to $1.82 per share, payable February 16, 2027 to shareholders of record January 15, 2027.
Exhibit 99.1 view on EDGAR → -
medium
Completed acquisition of Apogee Therapeutics, adding late-stage immunology assets including zumilokibart for atopic dermatitis and APG273 for asthma.
Exhibit 99.1 view on EDGAR →
Summary
AbbVie delivered strong third-quarter results, with revenue up 10.3% to $17.404 billion and adjusted diluted EPS more than doubling to $3.82. The company raised its full-year adjusted EPS guidance to $13.95–$13.99, reflecting confidence in continued momentum despite a $0.69 per share headwind from acquired IPR&D and milestones.
The board also increased the quarterly dividend by 5.2% to $1.82 per share, continuing AbbVie's long track record of dividend growth. In addition, AbbVie completed its acquisition of Apogee Therapeutics, deepening its immunology pipeline with late-stage assets targeting dermatologic, respiratory, and other inflammatory diseases.
The acquisition adds zumilokibart for atopic dermatitis and APG273 for asthma, strengthening AbbVie's position in key therapeutic areas. For retail investors, the raised guidance and dividend increase signal management's confidence in the business, while the Apogee acquisition supports long-term pipeline growth. The results and outlook are consistent with AbbVie's strategy of delivering strong financial performance and returning capital to shareholders.
Section-by-Section Diff
Event · Exhibit 99.1
AbbVie reports strong Q3 2026 results, raises FY2026 EPS guidance, and increases its quarterly dividend by 5.2%.
Added in current filing · view on EDGAR →
Worldwide net revenues were $17.404 billion, an increase of 10.3 percent on a reported basis, or 10.5 percent on an operational basis.
AbbVie's third-quarter revenue grew double digits year-over-year, driven by strong performance in immunology and neuroscience. This top-line growth supports the company's raised full-year guidance.
Added in current filing · view on EDGAR →
Diluted earnings per share (EPS) in the third quarter was $2.37 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $3.82.
GAAP EPS more than doubled from the prior-year quarter, while adjusted EPS also more than doubled. The results include an unfavorable $0.11 per share impact from acquired IPR&D and milestones expense.
Added in current filing · view on EDGAR →
AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026.
Management increased the full-year adjusted EPS outlook, reflecting confidence in continued momentum. The new range is above the prior midpoint and includes a known headwind from acquired IPR&D and milestones.
Added in current filing · view on EDGAR →
AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.73 per share to $1.82 per share beginning with the dividend payable on February 16, 2027 to shareholders of record as of January 15, 2027.
The quarterly dividend rises by approximately 5.2%, continuing AbbVie's long track record of dividend growth. The new dividend is payable in February 2027.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Nov 2, 2026 · How we verify